Lipoprotein-associated phospholipase A2 activity and risk of recurrent stroke

Mitchell S V Elkind, Wanling Tai, Kristen Coates, Myunghee C. Paik, Ralph L Sacco

Research output: Contribution to journalArticle

53 Citations (Scopus)

Abstract

Background: Mass levels of lipoprotein-associated phospholipase A 2 (Lp-PLA2), a leukocyte-derived enzyme involved in the metabolism of low-density lipoprotein to pro-inflammatory mediators, are associated with prognosis after stroke. Lp-PLA2 mass correlates only moderately with levels of Lp-PLA2 activity. The relationship of Lp-PLA2 activity to risk of stroke recurrence is unknown. We hypothesized that Lp-PLA2 activity levels would predict risk of recurrence. Methods: In the population-based Northern Manhattan Stroke Study, first ischemic stroke patients ≥40 years were followed for recurrent stroke. Levels of Lp-PLA2 activity were assessed in 467 patients, and categorized by quartile. Cox proportional hazard models were used to calculate hazard ratios (HR) and 95% confidence intervals (95% CI) for risk of recurrent stroke associated with marker quartiles after adjusting for demographics, vascular risk factors, and high-sensitivity C-reactive protein (hsCRP). Results: Mean age was 68.9 ± 12.7 years; 54.6% were women; 53.3% Hispanic, 27.2% black, and 17.8% white. Median follow-up was 4.0 years, and there were 80 recurrent strokes. Compared to the lowest quartile of Lp-PLA2 activity, those in the highest had an increased risk of recurrent stroke (adjusted HR 2.54, 95% CI 1.01-6.39). Conclusion: Stroke patients withLp-PLA2 activity levels in the highest quartile, compared to those in the lowest quartile, had an increased risk of recurrence after first ischemic stroke. Further studies are warranted to determine whether this biomarker has clinical utility in determining high-risk populations of stroke survivors, and whether anti-inflammatory strategies that reduce levels of activity of Lp-PLA2 reduce the risk of stroke recurrence.

Original languageEnglish
Pages (from-to)42-50
Number of pages9
JournalCerebrovascular Diseases
Volume27
Issue number1
DOIs
StatePublished - Jan 1 2009

Fingerprint

1-Alkyl-2-acetylglycerophosphocholine Esterase
Stroke
Recurrence
Confidence Intervals
LDL Lipoproteins
Hispanic Americans
Proportional Hazards Models
C-Reactive Protein
Population

Keywords

  • Anti-inflammatory strategies
  • C-reactive protein
  • Ischemic stroke
  • Lipoprotein-associated phospholipase A
  • Pro-inflammatory mediators
  • Recurrent stroke

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology
  • Cardiology and Cardiovascular Medicine

Cite this

Lipoprotein-associated phospholipase A2 activity and risk of recurrent stroke. / Elkind, Mitchell S V; Tai, Wanling; Coates, Kristen; Paik, Myunghee C.; Sacco, Ralph L.

In: Cerebrovascular Diseases, Vol. 27, No. 1, 01.01.2009, p. 42-50.

Research output: Contribution to journalArticle

Elkind, Mitchell S V ; Tai, Wanling ; Coates, Kristen ; Paik, Myunghee C. ; Sacco, Ralph L. / Lipoprotein-associated phospholipase A2 activity and risk of recurrent stroke. In: Cerebrovascular Diseases. 2009 ; Vol. 27, No. 1. pp. 42-50.
@article{bd2288eaf89d40908eb8fe11018a1ae6,
title = "Lipoprotein-associated phospholipase A2 activity and risk of recurrent stroke",
abstract = "Background: Mass levels of lipoprotein-associated phospholipase A 2 (Lp-PLA2), a leukocyte-derived enzyme involved in the metabolism of low-density lipoprotein to pro-inflammatory mediators, are associated with prognosis after stroke. Lp-PLA2 mass correlates only moderately with levels of Lp-PLA2 activity. The relationship of Lp-PLA2 activity to risk of stroke recurrence is unknown. We hypothesized that Lp-PLA2 activity levels would predict risk of recurrence. Methods: In the population-based Northern Manhattan Stroke Study, first ischemic stroke patients ≥40 years were followed for recurrent stroke. Levels of Lp-PLA2 activity were assessed in 467 patients, and categorized by quartile. Cox proportional hazard models were used to calculate hazard ratios (HR) and 95{\%} confidence intervals (95{\%} CI) for risk of recurrent stroke associated with marker quartiles after adjusting for demographics, vascular risk factors, and high-sensitivity C-reactive protein (hsCRP). Results: Mean age was 68.9 ± 12.7 years; 54.6{\%} were women; 53.3{\%} Hispanic, 27.2{\%} black, and 17.8{\%} white. Median follow-up was 4.0 years, and there were 80 recurrent strokes. Compared to the lowest quartile of Lp-PLA2 activity, those in the highest had an increased risk of recurrent stroke (adjusted HR 2.54, 95{\%} CI 1.01-6.39). Conclusion: Stroke patients withLp-PLA2 activity levels in the highest quartile, compared to those in the lowest quartile, had an increased risk of recurrence after first ischemic stroke. Further studies are warranted to determine whether this biomarker has clinical utility in determining high-risk populations of stroke survivors, and whether anti-inflammatory strategies that reduce levels of activity of Lp-PLA2 reduce the risk of stroke recurrence.",
keywords = "Anti-inflammatory strategies, C-reactive protein, Ischemic stroke, Lipoprotein-associated phospholipase A, Pro-inflammatory mediators, Recurrent stroke",
author = "Elkind, {Mitchell S V} and Wanling Tai and Kristen Coates and Paik, {Myunghee C.} and Sacco, {Ralph L}",
year = "2009",
month = "1",
day = "1",
doi = "10.1159/000172633",
language = "English",
volume = "27",
pages = "42--50",
journal = "Cerebrovascular Diseases",
issn = "1015-9770",
publisher = "S. Karger AG",
number = "1",

}

TY - JOUR

T1 - Lipoprotein-associated phospholipase A2 activity and risk of recurrent stroke

AU - Elkind, Mitchell S V

AU - Tai, Wanling

AU - Coates, Kristen

AU - Paik, Myunghee C.

AU - Sacco, Ralph L

PY - 2009/1/1

Y1 - 2009/1/1

N2 - Background: Mass levels of lipoprotein-associated phospholipase A 2 (Lp-PLA2), a leukocyte-derived enzyme involved in the metabolism of low-density lipoprotein to pro-inflammatory mediators, are associated with prognosis after stroke. Lp-PLA2 mass correlates only moderately with levels of Lp-PLA2 activity. The relationship of Lp-PLA2 activity to risk of stroke recurrence is unknown. We hypothesized that Lp-PLA2 activity levels would predict risk of recurrence. Methods: In the population-based Northern Manhattan Stroke Study, first ischemic stroke patients ≥40 years were followed for recurrent stroke. Levels of Lp-PLA2 activity were assessed in 467 patients, and categorized by quartile. Cox proportional hazard models were used to calculate hazard ratios (HR) and 95% confidence intervals (95% CI) for risk of recurrent stroke associated with marker quartiles after adjusting for demographics, vascular risk factors, and high-sensitivity C-reactive protein (hsCRP). Results: Mean age was 68.9 ± 12.7 years; 54.6% were women; 53.3% Hispanic, 27.2% black, and 17.8% white. Median follow-up was 4.0 years, and there were 80 recurrent strokes. Compared to the lowest quartile of Lp-PLA2 activity, those in the highest had an increased risk of recurrent stroke (adjusted HR 2.54, 95% CI 1.01-6.39). Conclusion: Stroke patients withLp-PLA2 activity levels in the highest quartile, compared to those in the lowest quartile, had an increased risk of recurrence after first ischemic stroke. Further studies are warranted to determine whether this biomarker has clinical utility in determining high-risk populations of stroke survivors, and whether anti-inflammatory strategies that reduce levels of activity of Lp-PLA2 reduce the risk of stroke recurrence.

AB - Background: Mass levels of lipoprotein-associated phospholipase A 2 (Lp-PLA2), a leukocyte-derived enzyme involved in the metabolism of low-density lipoprotein to pro-inflammatory mediators, are associated with prognosis after stroke. Lp-PLA2 mass correlates only moderately with levels of Lp-PLA2 activity. The relationship of Lp-PLA2 activity to risk of stroke recurrence is unknown. We hypothesized that Lp-PLA2 activity levels would predict risk of recurrence. Methods: In the population-based Northern Manhattan Stroke Study, first ischemic stroke patients ≥40 years were followed for recurrent stroke. Levels of Lp-PLA2 activity were assessed in 467 patients, and categorized by quartile. Cox proportional hazard models were used to calculate hazard ratios (HR) and 95% confidence intervals (95% CI) for risk of recurrent stroke associated with marker quartiles after adjusting for demographics, vascular risk factors, and high-sensitivity C-reactive protein (hsCRP). Results: Mean age was 68.9 ± 12.7 years; 54.6% were women; 53.3% Hispanic, 27.2% black, and 17.8% white. Median follow-up was 4.0 years, and there were 80 recurrent strokes. Compared to the lowest quartile of Lp-PLA2 activity, those in the highest had an increased risk of recurrent stroke (adjusted HR 2.54, 95% CI 1.01-6.39). Conclusion: Stroke patients withLp-PLA2 activity levels in the highest quartile, compared to those in the lowest quartile, had an increased risk of recurrence after first ischemic stroke. Further studies are warranted to determine whether this biomarker has clinical utility in determining high-risk populations of stroke survivors, and whether anti-inflammatory strategies that reduce levels of activity of Lp-PLA2 reduce the risk of stroke recurrence.

KW - Anti-inflammatory strategies

KW - C-reactive protein

KW - Ischemic stroke

KW - Lipoprotein-associated phospholipase A

KW - Pro-inflammatory mediators

KW - Recurrent stroke

UR - http://www.scopus.com/inward/record.url?scp=56149116581&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=56149116581&partnerID=8YFLogxK

U2 - 10.1159/000172633

DO - 10.1159/000172633

M3 - Article

VL - 27

SP - 42

EP - 50

JO - Cerebrovascular Diseases

JF - Cerebrovascular Diseases

SN - 1015-9770

IS - 1

ER -